JANX-009

N/A

Report date: 2025/06/11 11:17:33

Base Information

Drug NameJANX-009
Drug Alias NameJXA-2241.01Dual PD-L1 Checkpoint Inhibitor/CD28 Costimulator (Janux Therapeutics)PD-L1 x CD28 TRACIrPD-L1 x CD28 costimulatory TRACIr (Janux Therapeutics)JXA-2241 +[6] 
ClassificationBiologics
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsProgrammed death-ligand 1 blockersT lymphocytes stimulants +[4] 
TargetsT-cell-specific surface glycoprotein CD28Programmed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJanux Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJanux Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A